IDEXX Raises 2025 Outlook After Strong Q1 Results

IDEXX Laboratories reported Q1 2025 adjusted earnings per share of $2.96 and revenue of $998 million, outperforming earnings estimates but narrowly missing consensus revenue expectations. The company raised its full-year profit forecast to between $11.93 and $12.43 per share and revenue to between $4.10 billion and $4.21 billion, both above its previous guidance. Increased demand for animal diagnostic products and higher customer retention contributed to the strong performance. IDEXX has a history of beating earnings estimates and remains well-positioned in a growing animal diagnostics market. In contrast, IDEX Corporation, a manufacturer of engineered products, surpassed Q1 earnings and revenue expectations but faces slower long-term growth and shrinking margins amid industrial sector challenges. The results highlight IDEXX Laboratories' robust outlook compared to mixed performance in related industries.